Compare Abbott Laboratories (ABT) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Synopsys, Inc. — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Synopsys, Inc. trades at $432.21 (market cap $83.61B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.63% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| ABT | SNPS | |
|---|---|---|
Market Cap | $166.94B | $83.61B |
Sector | Health | Technology |
52-Week High | $136.62 | $645.59 |
52-Week Low | $82.57 | $380.47 |
Enterprise Value | $193.69B | $91.96B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
Synopsys (SNPS) trades at $436.63, down 0.12% on the day, with a bearish technical signal despite strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.35 exceeding expectations, and maintains robust gross margins of 73.47%. Recent news highlights the company's strategic pivot toward AI-driven design tools, though cash flow trends show volatility with a net outflow of $1.01B in 2025.
Outlook remains positive with a consensus price target of $558.33 implying 28% upside, driven by AI adoption and market positioning. Key risks include high valuation multiples (P/E of 101.21) and execution challenges in shifting business focus. Investors should weigh growth potential against premium pricing and competitive pressures in the semiconductor software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
